Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faecal bacteriotherapy for postantibiotic diarrhoea in critically ill patients
2021-002290-25Phase 4Active
- Sponsor
- Donatio intensivistam
- Start
- Nov 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of faecal bacteriotherapy solution in antibiotic-associated diarrhea (AAD), sponsored by Donatio intensivistam. Primary endpoint: Treatment failure at day 7. Started Nov 2022; status: active.
02
Drugs
faecal bacteriotherapy solution
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on 2021-002290-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002290-25.